This fluid (with pathogens) is then pumped into a “lab-on-chip” chamber fitted with four electronic circuits each coated with a unique aptamer fed from a replaceable cartridge. The aptamer generates a readable electronic signal upon finding-and-binding to any one of the four specific target pathogens. The device completes a full cycle from sample collection to graphical/numeric output within five minutes, analyzes both pathogen presence and concentrations, and repeats continuously.
The Bioradar Handheld Detector can be used alone, or in conjunction with other AptAvian™ detection and surveillance products to assure defense in depth when protecting farm areas and enclosures from airborne, waterborne, and other transmission mechanisms.
Comprised of five sections, the aptagenic™ assays can detect two pathogens. A test sample is deposited on the conjugate pad, and the mixture of sample, conjugates and control react and migrate along the assay strip through a transfer section, the first pathogen test, the second pathogen test, ending in the control test.
The conjugate pad contains two AptaSwitches™ one for each of the two pathogens and a control. Each particle of the first pathogen will react with its conjugate and then anchor to one of the multiple moorings on the first pathogen test section. Each of the second pathogen particles will react with its conjugate and then anchor to one of the different moorings on the second pathogen test section. The third type of mooring on the control section captures the control.
Building on live-animal field tests performed in Canada, aptagenic™ therapeutic development is underway for two pathogen-based diseases affecting pigs—Porcine Reproductive and Respiratory Syndrome (PRRS) and M. Hyopneumonia. Successful testing included inoculating all animals with pathogens after which separated groups received the nebulized aptagenic™ therapeutics. In both cases, the animals receiving aptagenic™ therapeutics experienced better recoveries—including avoided euthanasia—compared to the control groups receiving either no treatment or a standard alternative.
Aptagenic™ solutions are on the way for poultry as well, before intensifying pandemics recur. Building on results, data, and continuous product improvements in these detection, surveillance, and animal therapeutics, AptAvain™ will continue research and development to field our most important product goal—nebulizer-based therapeutics for use in humans.
Copyright © 2024 AptAvian™ - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.